NCT07103031Completed
Comorbidity-Based Propranolol Use in Pediatric Migraine
Targeting The Right Pediatric Migraine Patient: A Comorbidity-Oriented Approach To Propranolol Prophylaxis
Source: ClinicalTrials.gov · Last updated 5 Aug 2025
Brief summary (registry, in English)
This observational retrospective cohort study aims to identify clinical and biochemical predictors of response to propranolol prophylaxis in pediatric migraine. A total of 178 children diagnosed with migraine between 2021 and 2023 were evaluated based on headache-related disability (PedMIDAS) and pain severity (VAS). Patients were treated either with behavioral therapy or propranolol (1-3 mg/kg/day) for 3 months.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 488 (actual)
- First submitted
- 14 Jul 2025
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Kayseri University
- Diseases
- Migraine
- NCT number
- NCT07103031
What you commit to
- Study type: Observational
- Participants enrolled: 488
- From 1 Jan 2021 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Failure to meet ICHD-3 diagnostic criteria for primary headache
- Presence of structural brain lesions or other neurological disorders
- Chronic systemic illness or current use of other migraine prophylactic medications
Lab values
- Diagnosis of secondary headache, based on clinical history, family history, neurological examination, or laboratory/imaging findings
Other
- Incomplete data or loss to follow-up within the 3-month period
Who the study is looking for
- Children aged 0-20 years
- Diagnosed with primary headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)
- Clinical and/or neurological evaluation consistent with primary headache
- Completed baseline PedMIDAS and VAS assessments
- Available for 3-month follow-up after initiation of treatment
Age in the registry: 2 years to 19 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kayseri University Coordinator of this site? Confirm its status | Kayseri | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.